Procter & Gamble (P&G) has agreed to buy the consumer health business of German drugmaker Merck for €3.4billion (US$4.2 billion), as the US group struggles to ignite sales of its household brands.
The acquisition will give P&G, which owns a wealth of brand names from Pampers diapers to Gillette razors, control of vitamin makers including Seven Seas and Neurobion, which are faster-growing than P&G’s household products.
David Taylor, chief executive of P&G, said the over-the-counter healthcare business would offer “steady, broad-based growth.”
The deal was announced on the same day that the company unveiled another quarter of anemic sales growth and shrinking profit margins as it grapples with discounting from retailers and declining pricing power for its decades-old brands. `
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI